Loncastuximab tesirine – July 2026

  • Brand names:
    • Zynlonta®
  • Pharmaceutical Company:
    • SWEDISH ORPHAN BIOVITRUM PTY LTD
  • Condition/Indication: Diffuse large B-cell lymphoma (DLBCL)
  • Meeting Date: July 2026
Public Summary Documents
Related Public Summary Documents
Last updated
12 November 2026